AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

AbbVie's rheumatoid arthritis blockbuster Humira is set for $15 billion in revenues this year, but the first biosimilars could be on the US market as early as next year. The US company had pinned ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

Its forward dividend yield is a juicy 3.4%. For a while, though, AbbVie might not have been viewed as a fabulous pick by many ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...